» Articles » PMID: 35313461

Multifunctional Targeting Liposomes of Epirubicin Plus Resveratrol Improved Therapeutic Effect on Brain Gliomas

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2022 Mar 22
PMID 35313461
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The inability of many therapeutic molecules to cross the blood-brain barrier (BBB) combined with poor penetration into tumor tissue leads to difficult challenges for treatment of brain tumors. In order to settle these hurdles, we developed a novel multifunctional targeting carrier which enables drugs to transport across the BBB and targets brain tumor tissues.

Methods: In the multifunctional targeting liposomes, the natural compound resveratrol (RES) was incorporated into the lipid bilayer membranes of liposomes, while p-aminophenyl-α-D-manno-pyranoside (MAN) and wheat germ agglutinin (WGA) were conjugated to the liposomal surface. Epirubicin (EPI) as an anticancer drug was then loaded into liposomes. Then, liposomes were characterized by evaluation on particle size, zeta potential and apparent morphology. The epirubicin plus resveratrol liposomes modified with WGA and MAN were applied to glioma cells and BBB model in vitro and C6 glioma-bearing rats in vivo.

Results: The multifunctional targeting liposomes were round shaped with a smooth surface and uniform particle size. In consideration of the SRB results, the multifunctional targeting liposomes indicated a significant inhibitory effect, suggesting that MAN plus WGA generated robust drug delivery effects into the brain tumor cells. The glioma cells after administering epirubicin plus resveratrol liposomes modified with WGA and MAN displayed the most significant uptake and apoptosis conducted by flow cytometry. In the multifunctional targeting effects assay, the epirubicin plus resveratrol liposomes modified with WGA and MAN exhibited the strongest effects of crossing the BBB and then targeting brain tumor cells. In tumor-bearing rats after applying multifunctional targeting liposomes, the median survival time was evidently observed as being markedly longer than other controls.

Conclusion: The epirubicin plus resveratrol liposomes modified with WGA and MAN exhibited strong ability to improve epirubicin and resveratrol transporting across the BBB and therapeutic effect on brain glioma, showing multifunctional targeting capability.

Citing Articles

Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.

Luo Q, Yang J, Yang M, Wang Y, Liu Y, Liu J Mater Today Bio. 2025; 31:101457.

PMID: 39896289 PMC: 11786670. DOI: 10.1016/j.mtbio.2025.101457.


Explainable drug repurposing via path based knowledge graph completion.

Jimenez A, Merino M, Parras J, Zazo S Sci Rep. 2024; 14(1):16587.

PMID: 39025897 PMC: 11258358. DOI: 10.1038/s41598-024-67163-x.


Potential of Natural Phenolic Compounds against Doxorubicin-Induced Chemobrain: Biological and Molecular Mechanisms Involved.

Serini S, Calviello G Antioxidants (Basel). 2024; 13(4).

PMID: 38671933 PMC: 11047710. DOI: 10.3390/antiox13040486.


New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy.

Majchrzak-Celinska A, Studzinska-Sroka E Molecules. 2024; 29(7).

PMID: 38611962 PMC: 11013944. DOI: 10.3390/molecules29071682.


The Lipidomic Signature of Glioblastoma: A Promising Frontier in Cancer Research.

Yu N, Aboud O Cancers (Basel). 2024; 16(6).

PMID: 38539424 PMC: 10968728. DOI: 10.3390/cancers16061089.


References
1.
Furtado D, Bjornmalm M, Ayton S, Bush A, Kempe K, Caruso F . Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Adv Mater. 2018; 30(46):e1801362. DOI: 10.1002/adma.201801362. View

2.
Liu J, Tang W, Fu M, Gong X, Kong L, Yao X . Development of R modified epirubicin-dihydroartemisinin liposomes for treatment of non-small-cell lung cancer. Artif Cells Nanomed Biotechnol. 2019; 47(1):1947-1960. DOI: 10.1080/21691401.2019.1615932. View

3.
Feijen E, Leisenring W, Stratton K, Ness K, van der Pal H, van Dalen E . Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncol. 2019; 5(6):864-871. PMC: 6490232. DOI: 10.1001/jamaoncol.2018.6634. View

4.
Perveen K, Masood F, Hameed A . Preparation, characterization and evaluation of antibacterial properties of epirubicin loaded PHB and PHBV nanoparticles. Int J Biol Macromol. 2019; 144:259-266. DOI: 10.1016/j.ijbiomac.2019.12.049. View

5.
LaPointe S, Perry A, Butowski N . Primary brain tumours in adults. Lancet. 2018; 392(10145):432-446. DOI: 10.1016/S0140-6736(18)30990-5. View